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Fig. A, Unadjusted outcomes and costs of endovascular aneurysm
repair (EVAR): 2000 to 2011. B, Adjusted outcomes and costs of
EVAR: 2009 to 2011 vs 2000 to 2002. CI, Conﬁdence interval; OR,
odds ratio.
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base of 6522 patients who underwent pancreatic resection at our hospital
from 1970 to 2014. A total of 128 patients had >6 months follow-up
with computed tomography imaging. Preoperative, intraoperative, and
postoperative factors were recorded. Patients with and without postopera-
tive PVR thrombosis were compared using univariate, multivariate, and
receiver-operating characteristic curve analyses.
Results: Patient survival was 100% at 1 month, 95% at 6 months,
83% at 1 year, and 54% on overall median follow-up of 194 days. Me-
dian survival was 14 6 26 months. Eighty-two percent of PVRs were
performed with a primary repair, 8.5% with interposition vein, 5.5%
with interposition prosthetic graft, and 4% with patch. PVR patency
was 100% at 1 day, 98% at 1 month, 91% at 6 months, and 83% at
1 year. Patients with PVR thrombosis were not signiﬁcantly different
from patients with a patent PVR in age, survival, preoperative comor-
bidities, tumor characteristics, perioperative blood loss or transfusion,
or postoperative complications. They were more likely to have preop-
erative chemotherapy (53% vs 9%, P ¼ .0001), radiation (35% vs 2%,
P ¼ .0001), prolonged operative time (610 6 91 vs 423 6 188 mi-
nutes, P ¼ .0001), and develop postoperative ascites (76% vs 22%,
P ¼ .0001). The number of patients who developed ascites in the
setting of tumor recurrence did not differ among those with throm-
bosed and patent PVR (38% vs 50%, P ¼ .7). Patients with PVR
thrombosis were more likely to have prosthetic graft placement than
patients with a patent PVR (18% vs 2.7%; odds ratio [OR], 7.7;
95% conﬁdence interval [CI], 1.4-42, P ¼ .03). PVR patency at
6 months was signiﬁcantly lower for graft reconstruction (0%)
compared with primary repair (95%, P ¼ .0004) and vein reconstruc-
tion (91%, P ¼ .04). On multivariate analysis, operative time (OR,
1.01; 95% CI, 1.01-1.02) and prosthetic graft placement (OR, 8.12;
95% CI, 1.1-74) were independent predictors of PVR thrombosis
(C statistic ¼ 0.88).
Conclusions: Long operative times and use of prosthetic grafts for
reconstruction are risk factors for postoperative portal vein thrombosis. Pri-
mary repair and vein interposition should be preferentially used for PVR in
the setting of pancreatic resection.
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Surgeon’s Intraoperative Assessments During Autogenous
Arteriovenous Fistula Creation Strongly Correlate With Early Fistula
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Objectives: Early ﬁstula thrombosis (EFT) is a cause of autogenous
arteriovenous ﬁstula (AVF) failure. We followed up a cohort of men and
women with newly created AVFs to identify baseline predictors of EFT.
Methods: Cases of EFT, deﬁned as thrombosis diagnosed by physical
examination or ultrasound imaging, that occurred #16 days of AVF crea-
tion among participants of the Hemodialysis Fistula Maturation (HFM)
Study were compared with 166 non-EFT controls selected from the study.
They were optimally matched on ﬁve prespeciﬁed variables: gender, age (6
8 years), diabetes, dialysis status, and surgeon AVF volume within the prior
3 years (6 70 cases). Conditional logistic regression models were ﬁt with
and without adjustment for use of oral antithrombotic medication at
enrollment.
Results: Twenty-nine cases (5.3%) of EFT occurred among the ﬁrst
544 participants of a targeted enrollment of 600. Of the factors consid-
ered, the surgeon’s intraoperative perceptions were most strongly associ-
ated with EFT: maturation success (unlikely, marginal, likely) per
category (odds ratio [OR], 9.71; conﬁdence interval [CI], 3.7-25.5;yNew England Society for Vascular SurgeryP < .0001); absence vs presence of any intraoperative thrill (OR, 36.5;
CI, 4.2-320; P ¼ .0006); and the surgeon’s subjective frustration during
the procedure (OR, 6.99; CI, 2.38-20.5; P ¼ .0002). Longer duration
of surgery, which in both full and matched data sets was associated
with absence of thrill (2.0 vs 1.6 hours in the full data set), frustration
(2.3 vs 1.6 hours), and lower predicted likelihood of success (2.3 vs
1.7 vs 1.6 hours), was also itself predictive of EFT (OR, 2.0 per hour;
CI, 1.1-3.4; P ¼ .013). When present, a reduced extent of intraoperative
thrill (to the proximal, middle, or distal third of forearm/arm from the
ﬁstula) was also associated with EFT (OR per third of forearm/arm,
3.87; CI, 1.16-12.9; P ¼ .014). An intraoperative assessment that matu-
ration success was unlikely or that it was marginal when also combined
with surgeon frustration predicted 48% of EFTs with 98% speciﬁcity,
positive predictive value of 54%, and negative predictive value of 97%.
EFT was associated with forearm (vs upper arm) AVF (OR, 2.83; CI,
1.05-7.61; P ¼ .04). Oral antithrombotic medication was not signiﬁ-
cantly associated with EFT.
Conclusions: Although EFT was infrequent among HFM Study
participants, this outcome was common when the surgeon expressed
substantial intraoperative concern.
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Objectives: The purpose of this study was to characterize the
evolution in the “value” of endovascular abdominal aortic aneurysm
repair (EVAR) by detailing changes in adjusted outcomes and costs
over time.>Eastern Vascular Society
Fig 1. Freedom from stroke/death for creatinine. SE, Standard error.
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to evaluate patient characteristics, outcomes, and perioperative costs
for elective EVAR performed for an intact abdominal aortic aneurysm
(AAA). Outcomes were adjusted for patient demographics and comor-
bidities and for hospital factors by multivariate analysis. Costs were
calculated from hospital cost-to-charge ratio ﬁles and adjusted to 2011
dollars.
Results: From 2000 to 2011, 185,249 patients underwent elective
EVAR for an intact AAA. The absolute rates of in-hospital major morbidity,
mortality, and procedural costs all decreased signiﬁcantly over time (P <
.0001; Fig, A). The prevalence of major comorbidities in patients undergo-
ing EVAR, including obesity, diabetes, and dyslipidemia, all increased signif-
icantly over time. After adjusting for multiple demographics, comorbidities,
and hospital-level factors, recent outcomes of EVAR (2009-2011) remain
superior to the early experience (2000-2002) with respect to mortality
and major complications (Fig, B).
Conclusions: Advanced technology is often implicated in escalating
health care spending, and the “value” (deﬁned as outcomes relative to
cost) of expensive, novel techniques is often questioned. From 2000 to
2011, the outcomes of EVAR improved signiﬁcantly despite a higher prev-
alence of comorbidities among patients undergoing repair. Concurrently,
procedure-associated costs declined. These ﬁndings highlight the increasing
“value” of EVAR over time.
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Objectives: This study evaluated whether increased experience with
endovascular abdominal aortic aneurysm (AAA) repair (EVAR) for ruptured
AAA (rAAA) has improved patient outcomes.
Methods: The National Surgical Quality Improvement Program
(NSQIP) database was queried, from the years 2005 to 2011, to identify pa-
tients who underwent EVAR for rAAA. A total of 803 EVAR procedures
were performed for rAAA. Procedures performed between 2005 and
2007 were placed into the early EVAR (E-EVAR) group and those per-
formed between 2008 and 2011 were placed into the late EVAR (L-
EVAR) group. Patient demographics, comorbidities, perioperative data,
and outcomes were compared.
Results: More EVAR procedures were performed for rAAA in the L-
EVAR group than in the E-EVAR group (124 vs 679, P < .01). The groups
were similar with regards to demographics and preoperative comorbid con-
ditions. There was a lower rate of acute renal failure (9% vs 15%, P ¼ .03),
pneumonia (11% vs 18%, P ¼ .03), and deep venous thrombosis (0% vs 2%,
p4 units) (16% vs 4%, P < .01). The L-EVAR group had shorter operative
times (173 vs 187 minutes, P < .01) despite the trend toward hemodynamic
instability. Mortality on the day of surgery (10% vs 10%, P ¼ .82) and 30-
day mortality (26% vs 24%, P ¼ .69) were not signiﬁcantly different between
E-EVAR and L-EVAR.
Conclusions: There has been an increase in the use of EVAR for he-
modynamically unstable patients with rAAA, with acceptable immediate and
30-day mortality rates. The ﬁndings may be attributed to an improvement
in EVAR devices and/or the surgeons’ comfort level with the use of
EVAR for rAAA. These data suggest that EVAR is an effective treatment
for rAAA even in the setting of an unstable patient.
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A. Stone, Albeir Y. Mousa, Will Jackson. West Virginia University,
Charleston Division, Charleston, WVa>Eastern Vascular SocietyObjective: Several studies have reported mixed results after carotid
endarterectomy (CEA) in patients with chronic renal insufﬁciency (CRI);
however, only a few used the glomerular ﬁltration rate (GFR; Modiﬁcation
of Diet in Renal Disease) to analyze long-term outcome.
Methods: A total of 926 patients who had GFR and/or serum
creatinine (Cr) were classiﬁed into normal (GFR $60 mL or Cr <1.5
mg/dL, group A), moderate CRI (GFR $30-59 mL or Cr $1.5-2.9
mg/dL, group B), and severe CRI (GFR <30 mL or Cr $3 mg/dL,
group C).
Results: The stroke and death rates (early and late [mean follow-up:
35 months]) were 9%, 18%, and 44% for Cr groups A, B, and C (P ¼
.0001) in contrast to 8%, 14%, and 26% for GFR groups A, B, and C (P
¼ .0003). The stroke-free survival rates at 1, 2, and 3 years were 97%,
94%, and 92%; 92%, 85%, and 81%; and 56%, 56%, and 56% for Cr groups
A, B, and C, respectively (P < .0001, Fig 1), in contrast to 98%, 95%, and
93%; 93%, 90%, and 86%; and 86%, 77%, and 73% for GFR groups A, B, and
C (P < .0001, Fig 2). These rates for asymptomatic patients at 1, 2, and 3
years were 97%, 95%, and 93%; 94%, 87%, and 82%; and 56%, 56%, and 56%
for Cr groups A, B, and C, respectively (P < .0001), in contrast to 98%,
95%, and 94%; 95%, 91%, and 86%; and 84%, 80%, and 75% for GFR groups
A, B, and C (P ¼ .0026). A multivariate analysis showed that Cr$3 mg/dL
and GFR <30 mL had a HR of stroke and death of 4.7 and 2.2, respectively
(P ¼ .008).
Conclusions: Cr and GFR were sensitive in detecting late stroke/
death after CEA in patients with CRI. Patients with severe CRI had
higher rates of early and late stroke/death; therefore, CEA for these pa-
tients (particularly asymptomatic patients) must be considered with
caution.
